The venture fund "Unicorn Capital" invests in the company "Dipiaron", which is developing an innovative drug for the treatment of diabetes mellitus
Unicorn Capital Partners, the management company of the PharMed Innovations venture Fund, has entered into an investment agreement with respect to Dipiaron, which has acquired an exclusive license for the development and commercialization of the drug of the same name from Volgograd State Medical University (VolgSMU). The total size of the round is not disclosed, however, it is known that according to its results, clinical trials of the 1st and 2nd phases should be completed, and preparations for the 3rd phase of clinical trials should be carried out.
The development is aimed at creating a new drug for the treatment of type 2 diabetes mellitus (DM2T), metabolic syndrome and obesity. There are more than 400 million patients with DM2T in the world, however, the effectiveness of diabetes treatment and its complications does not fully satisfy doctors and patients, and therefore, there is still a medical need for drugs that combine efficacy, safety, ease of use, and both in terms of glycemic control and reducing the frequency of associated complications.. "Dipiarone" is an oral agonist of the GPR119 receptor. It affects specialized cells of the gastrointestinal tract (gastrointestinal tract), stimulating the production of endogenous GLP-1, and thereby increases the production of insulin by beta cells of the pancreas and the sensitivity of cells to insulin. An important property of dipiarone is a decrease in food intake and a decrease in body weight. The drug may be highly effective in monotherapy and in combination with DPP-4 inhibitors. The drug is able to displace synthetic GLP-1 agonists in the second line of DM2T therapy due to a more convenient method of application. There are no analogues of the drug "Dipiaron" on the world market – this is an advanced, in the full sense of the word, innovative development of Russian science. The drug was created as part of the implementation of the Pharma 2020 program, by combining the efforts of leading doctors and pharmacologists of VolgSMU in partnership with the Chemrar Center.
Alexey Vinogradov, CEO and Managing Partner of Unicorn Capital Partners: We are following our strategy to promote the best achievements of Russian science in the practical plane, realizing that in addition to money, it requires great organizational efforts to combine medical, industrial, financial and entrepreneurial expertise. Dipiaron is one of the so far rare (unfortunately) cases when intellectual property created in a Russian scientific center is further developed under a license agreement with a startup company that attracts venture capital investments for this. We hope that with the support of Unicorn, the project has every chance to reach a new level – to demonstrate safety and effectiveness in clinical trials and, as a result, to help many millions of patients both in Russia and in the world."
Olga Golub, CEO of Dipiaron LLC: The path from an innovative idea to a finished product is not easy, especially for pharmaceutical developments of Russian institutes. We are inspired by the fact that the company's project, which has shown interesting and promising results in preclinical research, has received the support of Unicorn Capital Partners. Thanks to venture financing, the project has the opportunity to take the next extremely important step – to conduct clinical trials and prove the effectiveness of our development for the treatment of DM2T.
Shkarin Vladimir Vyacheslavovich, Rector of VolgSMU: We consider this a great achievement of our university and Volgograd pharmacologists, who have created several innovative drugs in recent years, of which the drug Angipur has successfully passed 2 phases of clinical trials, and Dipiarone and a compound under the code AB-19 (for the prevention of diabetic nephropathies) will soon enter clinical trials. Our University has established a Research Center for Innovative medicines specializing in such developments.
Unicorn Capital Partners is the management company of the PharMed Innovations venture fund, created with the participation of a Russian Venture Company and the Ministry of Industry and Trade of the Russian Federation to invest in innovative developments of medicines, medical devices and software for use in medicine. We combine the efforts of doctors, scientists, financiers and entrepreneurs to ensure that advanced scientific ideas grow into new world-class products available to patients. Website: www.unicpartners.com .
Dipiaron is an innovative biotechnological company, a participant in the Skolkovo project, engaged in a project to create a highly effective non—injectable drug for the treatment of DM2T. The drug under development is an oral agonist of the GPR119 receptor in specialized L- and K-cells of the epithelium of the gastrointestinal tract. The drug affects the physiological mechanisms of insulin secretion. In addition to reducing the level of glycemia, it is expected that the drug will contribute to a decrease in body weight, as well as the frequency of cardiac and nephrological complications of diabetes mellitus. Website: www.dipiaron.com
VolgSMU – Volgograd State Medical University, founded in 1935, is one of the oldest specialized medical educational institutions in Russia. He is widely known both in Russia and abroad - today more than 4,500 specialists with a diploma of VolgSMU work in 127 countries of the world. The achievements of the pharmaceutical scientific school of VolgSMU are also very significant. The university staff made a significant contribution to the creation of a number of well-known domestic medicines, many of them are already used in medicine. Volgograd scientists - Academician of the Russian Academy of Sciences, Chief Freelance Clinical Pharmacologist of the Russian Federation Vladimir Petrov, Academician of the Russian Academy of Sciences Alexander Spasov, Corresponding Member of the Russian Academy of Sciences Ivan Tyurenkov, Professor Alexander Ozerov and other university scientists actively participated in the development of such drugs as phenibut, phenotropil, asparkam-L, polycatan.
For more information, please contact:
ELIZAVETA ROZHDESTVENSKAYA
Unicorn Capital Partners
Tel: +7 (495) 790-45-05
Email: info@unicpartners.com
Unicorn Capital Partners, the management company of the PharMed Innovations venture Fund, has entered into an investment agreement with respect to Dipiaron, which has acquired an exclusive license for the development and commercialization of the drug of the same name from Volgograd State Medical University (VolgSMU). The total size of the round is not disclosed, however, it is known that according to its results, clinical trials of the 1st and 2nd phases should be completed, and preparations for the 3rd phase of clinical trials should be carried out.
The development is aimed at creating a new drug for the treatment of type 2 diabetes mellitus (DM2T), metabolic syndrome and obesity. There are more than 400 million patients with DM2T in the world, however, the effectiveness of diabetes treatment and its complications does not fully satisfy doctors and patients, and therefore, there is still a medical need for drugs that combine efficacy, safety, ease of use, and both in terms of glycemic control and reducing the frequency of associated complications.. "Dipiarone" is an oral agonist of the GPR119 receptor. It affects specialized cells of the gastrointestinal tract (gastrointestinal tract), stimulating the production of endogenous GLP-1, and thereby increases the production of insulin by beta cells of the pancreas and the sensitivity of cells to insulin. An important property of dipiarone is a decrease in food intake and a decrease in body weight. The drug may be highly effective in monotherapy and in combination with DPP-4 inhibitors. The drug is able to displace synthetic GLP-1 agonists in the second line of DM2T therapy due to a more convenient method of application. There are no analogues of the drug "Dipiaron" on the world market – this is an advanced, in the full sense of the word, innovative development of Russian science. The drug was created as part of the implementation of the Pharma 2020 program, by combining the efforts of leading doctors and pharmacologists of VolgSMU in partnership with the Chemrar Center.
Alexey Vinogradov, CEO and Managing Partner of Unicorn Capital Partners: We are following our strategy to promote the best achievements of Russian science in the practical plane, realizing that in addition to money, it requires great organizational efforts to combine medical, industrial, financial and entrepreneurial expertise. Dipiaron is one of the so far rare (unfortunately) cases when intellectual property created in a Russian scientific center is further developed under a license agreement with a startup company that attracts venture capital investments for this. We hope that with the support of Unicorn, the project has every chance to reach a new level – to demonstrate safety and effectiveness in clinical trials and, as a result, to help many millions of patients both in Russia and in the world."
Olga Golub, CEO of Dipiaron LLC: The path from an innovative idea to a finished product is not easy, especially for pharmaceutical developments of Russian institutes. We are inspired by the fact that the company's project, which has shown interesting and promising results in preclinical research, has received the support of Unicorn Capital Partners. Thanks to venture financing, the project has the opportunity to take the next extremely important step – to conduct clinical trials and prove the effectiveness of our development for the treatment of DM2T.
Shkarin Vladimir Vyacheslavovich, Rector of VolgSMU: We consider this a great achievement of our university and Volgograd pharmacologists, who have created several innovative drugs in recent years, of which the drug Angipur has successfully passed 2 phases of clinical trials, and Dipiarone and a compound under the code AB-19 (for the prevention of diabetic nephropathies) will soon enter clinical trials. Our University has established a Research Center for Innovative medicines specializing in such developments.
Unicorn Capital Partners is the management company of the PharMed Innovations venture fund, created with the participation of a Russian Venture Company and the Ministry of Industry and Trade of the Russian Federation to invest in innovative developments of medicines, medical devices and software for use in medicine. We combine the efforts of doctors, scientists, financiers and entrepreneurs to ensure that advanced scientific ideas grow into new world-class products available to patients. Website: www.unicpartners.com .
Dipiaron is an innovative biotechnological company, a participant in the Skolkovo project, engaged in a project to create a highly effective non—injectable drug for the treatment of DM2T. The drug under development is an oral agonist of the GPR119 receptor in specialized L- and K-cells of the epithelium of the gastrointestinal tract. The drug affects the physiological mechanisms of insulin secretion. In addition to reducing the level of glycemia, it is expected that the drug will contribute to a decrease in body weight, as well as the frequency of cardiac and nephrological complications of diabetes mellitus. Website: www.dipiaron.com
VolgSMU – Volgograd State Medical University, founded in 1935, is one of the oldest specialized medical educational institutions in Russia. He is widely known both in Russia and abroad - today more than 4,500 specialists with a diploma of VolgSMU work in 127 countries of the world. The achievements of the pharmaceutical scientific school of VolgSMU are also very significant. The university staff made a significant contribution to the creation of a number of well-known domestic medicines, many of them are already used in medicine. Volgograd scientists - Academician of the Russian Academy of Sciences, Chief Freelance Clinical Pharmacologist of the Russian Federation Vladimir Petrov, Academician of the Russian Academy of Sciences Alexander Spasov, Corresponding Member of the Russian Academy of Sciences Ivan Tyurenkov, Professor Alexander Ozerov and other university scientists actively participated in the development of such drugs as phenibut, phenotropil, asparkam-L, polycatan.
For more information, please contact:
ELIZAVETA ROZHDESTVENSKAYA
Unicorn Capital Partners
Tel: +7 (495) 790-45-05
Email: info@unicpartners.com